Work

Nivolumab and relatlimab as frontline therapy in advanced melanoma.

Year: 2022

Type: other

Source: PubMed

Author: Nikhil I Khushalani

Institution: Moffitt Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4303510313

Cites:

Cited by: 2

Related to: 10